Cargando…

Outcomes and Prognostic Factors of Patients with Urothelial Carcinoma Undergoing Radical Cystectomy and pT0 in the Final Histology Without Neoadjuvant Chemotherapy

PURPOSE: Absence of tumor in the final histopathology after radical cystectomy (RC) is a rare but potentially favorable outcome. Therefore, we aimed to analyze outcomes and prognostic factors of patients with urothelial carcinoma (UC) undergoing RC and T0 in the final histology without neoadjuvant c...

Descripción completa

Detalles Bibliográficos
Autores principales: Rodler, Severin, Buchner, Alexander, Eismann, Lennert, Schulz, Gerald Bastian, Marcon, Julian, Ledderose, Stephan, Schlenker, Boris, Stief, Christian G, Karl, Alexander, Jokisch, Jan-Friedrich
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9355019/
https://www.ncbi.nlm.nih.gov/pubmed/35937307
http://dx.doi.org/10.2147/RRU.S374068
_version_ 1784763200114262016
author Rodler, Severin
Buchner, Alexander
Eismann, Lennert
Schulz, Gerald Bastian
Marcon, Julian
Ledderose, Stephan
Schlenker, Boris
Stief, Christian G
Karl, Alexander
Jokisch, Jan-Friedrich
author_facet Rodler, Severin
Buchner, Alexander
Eismann, Lennert
Schulz, Gerald Bastian
Marcon, Julian
Ledderose, Stephan
Schlenker, Boris
Stief, Christian G
Karl, Alexander
Jokisch, Jan-Friedrich
author_sort Rodler, Severin
collection PubMed
description PURPOSE: Absence of tumor in the final histopathology after radical cystectomy (RC) is a rare but potentially favorable outcome. Therefore, we aimed to analyze outcomes and prognostic factors of patients with urothelial carcinoma (UC) undergoing RC and T0 in the final histology without neoadjuvant chemotherapy at a high-volume academic center. PATIENTS AND METHODS: We retrospectively analyzed patients undergoing RC for pure UC between 2004 and 2020. Cancer-specific survival (CSS) and overall survival (OS) were calculated using Kaplan–Meier analysis and group comparison by Log rank test. Potential prognostic factors were analyzed using univariate Cox regression models. RESULTS: A total of 1051 patients with UC underwent RC. 72 patients (6.7%) showed pT0 in the final histology. Across all T-stages, 5-year CSS was significantly different with 88% for pT0, 80% for pTa/pTis, 78% for pT1, 76% for pT2, 51% for pT3 and 27% for pT4 in our cohort (p=0.001). Neither instillation therapy (HR 0.31, 95% CI 0.07–1.43), number of TURB prior RC (HR 1.47, 95% CI 0.25–6.18), use of photodynamic diagnostics (PDD) (HR 0.64, 95% CI 0.14–3.02), performing a second resection (HR 0.87, 95% CI 0.27–2.86), muscle-invasive disease prior RC at any TURB (HR 0.7, 95% CI 0.2–2.39) or muscle-invasive disease in the TURB prior RC (HR 1.0, 0.31–3.29) were associated with CSS in univariate analysis. CONCLUSION: pT0 reveals a survival benefit in patients undergoing RC for UC and therefore presents a distinctive tumor entity. As clinical and cystoscopic characteristics do not improve patient stratification, further research is warranted to define risk groups in this specific tumor entity.
format Online
Article
Text
id pubmed-9355019
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-93550192022-08-06 Outcomes and Prognostic Factors of Patients with Urothelial Carcinoma Undergoing Radical Cystectomy and pT0 in the Final Histology Without Neoadjuvant Chemotherapy Rodler, Severin Buchner, Alexander Eismann, Lennert Schulz, Gerald Bastian Marcon, Julian Ledderose, Stephan Schlenker, Boris Stief, Christian G Karl, Alexander Jokisch, Jan-Friedrich Res Rep Urol Original Research PURPOSE: Absence of tumor in the final histopathology after radical cystectomy (RC) is a rare but potentially favorable outcome. Therefore, we aimed to analyze outcomes and prognostic factors of patients with urothelial carcinoma (UC) undergoing RC and T0 in the final histology without neoadjuvant chemotherapy at a high-volume academic center. PATIENTS AND METHODS: We retrospectively analyzed patients undergoing RC for pure UC between 2004 and 2020. Cancer-specific survival (CSS) and overall survival (OS) were calculated using Kaplan–Meier analysis and group comparison by Log rank test. Potential prognostic factors were analyzed using univariate Cox regression models. RESULTS: A total of 1051 patients with UC underwent RC. 72 patients (6.7%) showed pT0 in the final histology. Across all T-stages, 5-year CSS was significantly different with 88% for pT0, 80% for pTa/pTis, 78% for pT1, 76% for pT2, 51% for pT3 and 27% for pT4 in our cohort (p=0.001). Neither instillation therapy (HR 0.31, 95% CI 0.07–1.43), number of TURB prior RC (HR 1.47, 95% CI 0.25–6.18), use of photodynamic diagnostics (PDD) (HR 0.64, 95% CI 0.14–3.02), performing a second resection (HR 0.87, 95% CI 0.27–2.86), muscle-invasive disease prior RC at any TURB (HR 0.7, 95% CI 0.2–2.39) or muscle-invasive disease in the TURB prior RC (HR 1.0, 0.31–3.29) were associated with CSS in univariate analysis. CONCLUSION: pT0 reveals a survival benefit in patients undergoing RC for UC and therefore presents a distinctive tumor entity. As clinical and cystoscopic characteristics do not improve patient stratification, further research is warranted to define risk groups in this specific tumor entity. Dove 2022-08-01 /pmc/articles/PMC9355019/ /pubmed/35937307 http://dx.doi.org/10.2147/RRU.S374068 Text en © 2022 Rodler et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Rodler, Severin
Buchner, Alexander
Eismann, Lennert
Schulz, Gerald Bastian
Marcon, Julian
Ledderose, Stephan
Schlenker, Boris
Stief, Christian G
Karl, Alexander
Jokisch, Jan-Friedrich
Outcomes and Prognostic Factors of Patients with Urothelial Carcinoma Undergoing Radical Cystectomy and pT0 in the Final Histology Without Neoadjuvant Chemotherapy
title Outcomes and Prognostic Factors of Patients with Urothelial Carcinoma Undergoing Radical Cystectomy and pT0 in the Final Histology Without Neoadjuvant Chemotherapy
title_full Outcomes and Prognostic Factors of Patients with Urothelial Carcinoma Undergoing Radical Cystectomy and pT0 in the Final Histology Without Neoadjuvant Chemotherapy
title_fullStr Outcomes and Prognostic Factors of Patients with Urothelial Carcinoma Undergoing Radical Cystectomy and pT0 in the Final Histology Without Neoadjuvant Chemotherapy
title_full_unstemmed Outcomes and Prognostic Factors of Patients with Urothelial Carcinoma Undergoing Radical Cystectomy and pT0 in the Final Histology Without Neoadjuvant Chemotherapy
title_short Outcomes and Prognostic Factors of Patients with Urothelial Carcinoma Undergoing Radical Cystectomy and pT0 in the Final Histology Without Neoadjuvant Chemotherapy
title_sort outcomes and prognostic factors of patients with urothelial carcinoma undergoing radical cystectomy and pt0 in the final histology without neoadjuvant chemotherapy
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9355019/
https://www.ncbi.nlm.nih.gov/pubmed/35937307
http://dx.doi.org/10.2147/RRU.S374068
work_keys_str_mv AT rodlerseverin outcomesandprognosticfactorsofpatientswithurothelialcarcinomaundergoingradicalcystectomyandpt0inthefinalhistologywithoutneoadjuvantchemotherapy
AT buchneralexander outcomesandprognosticfactorsofpatientswithurothelialcarcinomaundergoingradicalcystectomyandpt0inthefinalhistologywithoutneoadjuvantchemotherapy
AT eismannlennert outcomesandprognosticfactorsofpatientswithurothelialcarcinomaundergoingradicalcystectomyandpt0inthefinalhistologywithoutneoadjuvantchemotherapy
AT schulzgeraldbastian outcomesandprognosticfactorsofpatientswithurothelialcarcinomaundergoingradicalcystectomyandpt0inthefinalhistologywithoutneoadjuvantchemotherapy
AT marconjulian outcomesandprognosticfactorsofpatientswithurothelialcarcinomaundergoingradicalcystectomyandpt0inthefinalhistologywithoutneoadjuvantchemotherapy
AT ledderosestephan outcomesandprognosticfactorsofpatientswithurothelialcarcinomaundergoingradicalcystectomyandpt0inthefinalhistologywithoutneoadjuvantchemotherapy
AT schlenkerboris outcomesandprognosticfactorsofpatientswithurothelialcarcinomaundergoingradicalcystectomyandpt0inthefinalhistologywithoutneoadjuvantchemotherapy
AT stiefchristiang outcomesandprognosticfactorsofpatientswithurothelialcarcinomaundergoingradicalcystectomyandpt0inthefinalhistologywithoutneoadjuvantchemotherapy
AT karlalexander outcomesandprognosticfactorsofpatientswithurothelialcarcinomaundergoingradicalcystectomyandpt0inthefinalhistologywithoutneoadjuvantchemotherapy
AT jokischjanfriedrich outcomesandprognosticfactorsofpatientswithurothelialcarcinomaundergoingradicalcystectomyandpt0inthefinalhistologywithoutneoadjuvantchemotherapy